BioPharma Resources

Drug Trial Radar · NCT02804763

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Jun 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

182

Actual

Start

Jun 2, 2016

Primary completion

May 31, 2018

Study completion Nov 19, 2018

Sponsor

Lead sponsor
UCB Biopharma S.P.R.L.UCB
Sponsor type
Industry
First posted
Jun 17, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus.

Conditions

  • Systemic Lupus Erythematosus (SLE)

Interventions

  • PlaceboDrug

    Solution for infusion, 0,9% saline

  • Dapirolizumab pegol (DZP)Drug

    Solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-Based Composite Lupus Assessment (BICLA) (mNRI) Response Across 3 Doses of Dapirolizumab Pegol (DZP) and Placebo (PBO) at Week 24Time frame: Week 24

Locations

71 sites in 13 countries. Site status is shown where the registry gives one.

  • Sl0023 312

    Birmingham, Alabama

  • Sl0023 307

    El Cajon, California

  • Sl0023 309

    El Cajon, California

  • Sl0023 323

    Huntington Beach, California

  • Sl0023 311

    Los Angeles, California

  • Sl0023 314

    Thousand Oaks, California

  • Sl0023 302

    Upland, California

  • Sl0023 326

    New Haven, Connecticut

  • Sl0023 304

    Clearwater, Florida

  • Sl0023 322

    DeBary, Florida

  • Sl0023 321

    Miami, Florida

  • Sl0023 301

    Miami Lakes, Florida

  • Sl0023 319

    Palm Harbor, Florida

  • Sl0023 310

    Tampa, Florida

  • Sl0023 324

    Atlanta, Georgia

  • Sl0023 327

    Stockbridge, Georgia

  • Sl0023 320

    Idaho Falls, Idaho

  • Sl0023 306

    Albuquerque, New Mexico

  • Sl0023 313

    Lake Success, New York

  • Sl0023 305

    Oklahoma City, Oklahoma

  • Sl0023 315

    Jackson, Tennessee

  • Sl0023 308

    Memphis, Tennessee

  • Sl0023 317

    Amarillo, Texas

  • Sl0023 303

    Houston, Texas

  • Sl0023 328

    Spokane, Washington

  • Sl0023 101

    Plovdiv, Bulgaria

  • Sl0023 102

    Plovdiv, Bulgaria

  • Sl0023 202

    Providencia, Chile

  • Sl0023 203

    Providencia, Chile

  • Sl0023 201

    Puerto Varas, Chile

  • Sl0023 204

    Viña del Mar, Chile

  • Sl0023 213

    Barranquilla, Colombia

  • Sl0023 212

    Bogotá, Colombia

  • Sl0023 214

    Bogotá, Colombia

  • Sl0023 216

    Bucaramanga, Colombia

  • Sl0023 211

    Chía, Colombia

  • Sl0023 215

    Medellín, Colombia

  • Sl0023 341

    Hanover, Germany

  • Sl0023 113

    Leipzig, Germany

  • Sl0023 124

    Debrecen, Hungary

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.